{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:51:06Z","timestamp":1774533066548,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,2]]},"DOI":"10.7759\/cureus.29833","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:38:01Z","timestamp":1664789881000},"source":"Crossref","is-referenced-by-count":4,"title":["Migraine and Current Pharmacologic Management"],"prefix":"10.7759","author":[{"given":"Okelue E","family":"Okobi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen G","family":"Boms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C","family":"Ijeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E","family":"Eboigbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kesena B","family":"Alex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adebisi A","family":"Adejola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uduak A","family":"Udo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donnee","family":"Athem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Oboh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eniola","family":"Olamilehin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oyintoun-emi","family":"Ozobokeme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeoluwa","family":"Adegbosin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Nwaeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Endurance O","family":"Evbayekha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Acute migraine headache: treatment strategies","volume":"97","author":"Mayans l","year":"2018","unstructured":"Mayans l, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018, 97:243-51.","journal-title":"Am Fam Physician"},{"key":"ref2","unstructured":"IHS Classification ICHD-3. Migraine. (2021). Accessed. September 8, 2022: https:\/\/ichd-3.org\/1-migraine\/."},{"key":"ref3","unstructured":"National Institute of Neurological Disorders and Stroke. Migraine. (2022). Accessed. September 8, 2022: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/migraine."},{"key":"ref4","unstructured":"Medscape. Migraine headache treatment & management. (2021). Accessed. September 8, 2022: https:\/\/emedicine.medscape.com\/article\/1142556-treatment#d11."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153","article-title":"The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani J","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021, 61:1021-39. 10.1111\/head.14153","journal-title":"Headache"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"Silberstein SD","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012, 78:1337-45. 10.1212\/WNL.0b013e3182535d20","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01130-5","article-title":"European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA)","volume":"21","author":"Sacco S","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, et al.. European Headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020, 21:76. 10.1186\/s10194-020-01130-5","journal-title":"J Headache Pain"},{"key":"ref8","unstructured":"2022 ICD-10-CM Diagnosis Code G43.909. (2022). Accessed. September 8, 2022: https:\/\/www.icd10data.com\/ICD10CM\/Codes\/G00-G99\/G40-G47\/G43-\/G43.909."},{"key":"ref9","unstructured":"American Headache Society. How to diagnose migraine. (2021). Accessed. September 12, 2022: https:\/\/americanheadachesociety.org\/wp-content\/uploads\/2021\/01\/AHS-First-Contact-Diagnosing-Migraine-.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/B0-12-226870-9\/00194-5","article-title":"Migraine with aura","author":"Silberstein SD","year":"2003","unstructured":"Silberstein SD. Migraine with aura. Encyclopedia of the Neurological Sciences. Aminoff MJ, Daroff RB (ed): Academic Press, Cambridge, MA; 2003. 174-9. 10.1016\/B0-12-226870-9\/00194-5"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1995626","article-title":"A rational approach to migraine diagnosis and management in primary care","volume":"53","author":"Martin VT","year":"2021","unstructured":"Martin VT, Feoktistov A, Solomon GD. A rational approach to migraine diagnosis and management in primary care. Ann Med. 2021, 53:1979-90. 10.1080\/07853890.2021.1995626","journal-title":"Ann Med"},{"key":"ref12","unstructured":"Canadian Headache Society. Guidelines. (2021). Accessed. September 12, 2022: https:\/\/headachesociety.ca\/guidelines\/."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/head.14024","article-title":"The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys","volume":"61","author":"Burch R","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021, 61:60-8. 10.1111\/head.14024","journal-title":"Headache"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1017\/S0317167100118943","article-title":"Canadian Headache Society guideline: acute drug therapy for migraine headache","volume":"40","author":"Worthington I","year":"2013","unstructured":"Worthington I, Pringsheim T, Gawel MJ, et al.. Canadian Headache Society guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013, 40:S1-S80.","journal-title":"Can J Neurol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1017-9","article-title":"Advances in genetics of migraine","volume":"20","author":"Sutherland HG","year":"2019","unstructured":"Sutherland HG, Albury CL, Griffiths LR. Advances in genetics of migraine. J Headache Pain. 2019, 20:72. 10.1186\/s10194-019-1017-9","journal-title":"J Headache Pain"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-009-0273-0","article-title":"Future drugs for migraine","volume":"4","author":"Farinelli I","year":"2009","unstructured":"Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P. Future drugs for migraine. Intern Emerg Med. 2009, 4:367-73. 10.1007\/s11739-009-0273-0","journal-title":"Intern Emerg Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2009.03.019","article-title":"Neurobiology of migraine","volume":"161","author":"Goadsby PJ","year":"2009","unstructured":"Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR. Neurobiology of migraine. Neuroscience. 2009, 161:327-41. 10.1016\/j.neuroscience.2009.03.019","journal-title":"Neuroscience"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.aat.2012.05.002","article-title":"Migraine diagnosis: screening items, instruments, and scales","volume":"50","author":"Peng KP","year":"2012","unstructured":"Peng KP, Wang SJ. Migraine diagnosis: screening items, instruments, and scales. Acta Anaesthesiol Taiwan. 2012, 50:69-73. 10.1016\/j.aat.2012.05.002","journal-title":"Acta Anaesthesiol Taiwan"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/2049463712459691","article-title":"Headache disorders: differentiating and managing the common subtypes","volume":"6","author":"Ahmed F","year":"2012","unstructured":"Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain. 2012, 6:124-32. 10.1177\/2049463712459691","journal-title":"Br J Pain"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7939","article-title":"Acute treatments for episodic migraine in adults: a systematic review and meta-analysis","volume":"325","author":"VanderPluym JH","year":"2021","unstructured":"VanderPluym JH, Halker Singh RB, Urtecho M, et al.. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021, 325:2357-69. 10.1001\/jama.2021.7939","journal-title":"JAMA"},{"key":"ref21","article-title":"The pharmacological management of migraine, part 1: overview and abortive therapy","volume":"33","author":"DeMaagd G","year":"2008","unstructured":"DeMaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T. 2008, 33:404-16.","journal-title":"P T"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00577.x","article-title":"Modifiable risk factors for migraine progression","volume":"46","author":"Bigal ME","year":"2006","unstructured":"Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006, 46:1334-43. 10.1111\/j.1526-4610.2006.00577.x","journal-title":"Headache"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1038-4","article-title":"Current and emerging evidence-based treatment options in chronic migraine: a narrative review","volume":"20","author":"Agostoni EC","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P, et al.. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019, 20:92. 10.1186\/s10194-019-1038-4","journal-title":"J Headache Pain"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.13.1443","article-title":"Sumatriptan-naproxen for acute treatment of migraine: a randomized trial","volume":"297","author":"Brandes JL","year":"2007","unstructured":"Brandes JL, Kudrow D, Stark SR, et al.. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007, 297:1443-54. 10.1001\/jama.297.13.1443","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0703-0","article-title":"Network meta-analysis of migraine disorder treatment by NSAIDs and triptans","volume":"17","author":"Xu H","year":"2016","unstructured":"Xu H, Han W, Wang J, Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016, 17:113. 10.1186\/s10194-016-0703-0","journal-title":"J Headache Pain"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130733","article-title":"A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache","volume":"10","author":"Jackson JL","year":"2015","unstructured":"Jackson JL, Cogbill E, Davila RS, et al.. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. Plos one. 2015, 10:e0130733. 10.1371\/journal.pone.0130733","journal-title":"Plos one"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212785","article-title":"Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis","volume":"14","author":"Jackson JL","year":"2019","unstructured":"Jackson JL, Kuriyama A, Kuwatsuka Y, et al.. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019, 14:e0212785. 10.1371\/journal.pone.0212785","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1984.0402091.x","article-title":"Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study","volume":"4","author":"Kangasniemi P","year":"1984","unstructured":"Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia. 1984, 4:91-6. 10.1046\/j.1468-2982.1984.0402091.x","journal-title":"Cephalalgia"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1991.hed3105333.x","article-title":"Propranolol in the management of recurrent migraine: a meta-analytic review","volume":"31","author":"Holroyd KA","year":"1991","unstructured":"Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache. 1991, 31:333-40. 10.1111\/j.1526-4610.1991.hed3105333.x","journal-title":"Headache"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000005111","article-title":"Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine","volume":"143","author":"Bruloy E","year":"2019","unstructured":"Bruloy E, Sinna R, Grolleau JL, Bout-Roumazeilles A, Berard E, Chaput B. Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine. Plast Reconstr Surg. 2019, 143:239-50. 10.1097\/PRS.0000000000005111","journal-title":"Plast Reconstr Surg"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/1028415X.2021.1904542","article-title":"Effect of vitamin B2 supplementation on migraine prophylaxis: a systematic review and meta-analysis","volume":"25","author":"Chen YS","year":"2022","unstructured":"Chen YS, Lee HF, Tsai CH, et al.. Effect of vitamin B2 supplementation on migraine prophylaxis: a systematic review and meta-analysis. Nutr Neurosci. 2022, 25:1801-12. 10.1080\/1028415X.2021.1904542","journal-title":"Nutr Neurosci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102961","article-title":"TREK channel activation suppresses migraine pain phenotype","volume":"24","author":"\u00c1valos Prado P","year":"2021","unstructured":"\u00c1valos Prado P, Landra-Willm A, Verkest C, Ribera A, Chassot AA, Baron A, Sandoz G. TREK channel activation suppresses migraine pain phenotype. iScience. 2021, 24:102961. 10.1016\/j.isci.2021.102961","journal-title":"iScience"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/head.13081","article-title":"The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine","volume":"57","author":"Edvinsson L","year":"2017","unstructured":"Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017, 57:47-55. 10.1111\/head.13081","journal-title":"Headache"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/B0-44-306557-8\/50212-4","article-title":"Neurologic symptoms of migraine","author":"Spierings ELH","year":"2003","unstructured":"Spierings ELH. Neurologic symptoms of migraine. Office Practice of Neurology (Second Edition). Samuels MA, Feske SK, Daffner KR (ed): Churchill Livingstone, London, UK; 2003. 1330-5. 10.1016\/B0-44-306557-8\/50212-4"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1024-x","article-title":"Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)","volume":"20","author":"Silberstein SD","year":"2019","unstructured":"Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019, 20:75. 10.1186\/s10194-019-1024-x","journal-title":"J Headache Pain"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000983","article-title":"Pathophysiology of migraine","volume":"27","author":"Recober A","year":"2021","unstructured":"Recober A. Pathophysiology of migraine. Continuum (Minneap Minn). 2021, 27:586-96. 10.1212\/CON.0000000000000983","journal-title":"Continuum (Minneap Minn)"},{"key":"ref37","unstructured":"FDA approves new treatment for adults with migraine. (2019). Accessed. September 10, 2022: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-adults-migraine."},{"key":"ref38","unstructured":"FDA. New drug class employs novel mechanism for migraine treatment and prevention. (2019). Accessed. September 13, 2022: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/new-drug-class-employs-novel-mechanism-migraine-treatment-and-preve...."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01264-5","article-title":"Ubrogepant: first approval","volume":"80","author":"Scott LJ","year":"2020","unstructured":"Scott LJ. Ubrogepant: first approval. Drugs. 2020, 80:323-8. 10.1007\/s40265-020-01264-5","journal-title":"Drugs"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01633-3","article-title":"Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis","volume":"20","author":"Deng H","year":"2020","unstructured":"Deng H, Li GG, Nie H, Feng YY, Guo GY, Guo WL, Tang ZP. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. BMC Neurol. 2020, 20:57. 10.1186\/s12883-020-01633-3","journal-title":"BMC Neurol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update","volume":"23","author":"Sacco S","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, et al.. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022, 23:67. 10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst F","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021, 22:128. 10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.649143","article-title":"Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis","volume":"12","author":"Wang X","year":"2021","unstructured":"Wang X, Chen Y, Song J, You C. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. Front Pharmacol. 2021, 12:649143. 10.3389\/fphar.2021.649143","journal-title":"Front Pharmacol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00834-9","article-title":"Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis","volume":"35","author":"Overeem LH","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs. 2021, 35:805-20. 10.1007\/s40263-021-00834-9","journal-title":"CNS Drugs"},{"key":"ref45","unstructured":"NCATS. Tonabersat. (2004). Accessed. September 14, 2022: https:\/\/drugs.ncats.io\/drug\/2XD9773ZMN."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01804.x","article-title":"Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis","volume":"29","author":"Goadsby PJ","year":"2009","unstructured":"Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia. 2009, 29:742-50. 10.1111\/j.1468-2982.2008.01804.x","journal-title":"Cephalalgia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/115610-migraine-and-current-pharmacologic-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:23Z","timestamp":1707507623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/115610-migraine-and-current-pharmacologic-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,2]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.29833","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,2]]}}}